Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Melanoma 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Lung Neoplasms 2Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Solid Tumors 1Solid Tumor, Adult 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Pancreatic Adenocarcinoma 1PD-L1-selected Solid Tumors 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Follicular 1

Interventions

Oxaliplatin 295Capecitabine 209Fluorouracil 183Cisplatin 172Docetaxel 140S 1 (combination) 135Paclitaxel 128Leucovorin 117Irinotecan 110pembrolizumab 104Trastuzumab 76Nivolumab 59apatinib 57Drug Therapy 52sintilimab 46Surgical Procedures, Operative 45Ramucirumab 40Radiotherapy 40Bevacizumab 37Hyperthermic Intraperitoneal Chemotherapy 34Epirubicin 32titanium silicide 31tislelizumab 31Carboplatin 31Gastrectomy 28Cyclophosphamide 27XELOX 25Tegafur 24Folfox protocol 23Albumin-Bound Paclitaxel 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Tiragolumab × Clear all
NCT04933227 2024-11-14

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Hoffmann-La Roche

Phase 2 Terminated
29 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡